Navigation Links
Emdeon Announces Clinical Services Agreement with ICA, Educational Sessions During HIMSS12
Date:2/16/2012

compliant and has been certified by an ONC-ATCB in accordance with the applicable certification criteria adopted by the Secretary of Health and Human Services. This certification does not represent an endorsement by the U.S. Department of Health and Human Services or guarantee the receipt of incentive payments. Emdeon Inc., 01/19/12, Emdeon Clinician 7.6, 0119201230701, NQF0064/PQRI128, NQF0041/PQRI110, NQF0024, NQF0028, NQF0038, NQF0059/PQRI1, NQF0064/PQRI2, NQF0061/PQRI3.

About Emdeon

Emdeon is a leading provider of revenue and payment cycle management and clinical information exchange solutions, connecting payers, providers and patients in the U.S. healthcare system. Emdeon's product and service offerings integrate and automate key business and administrative functions of its payer and provider customers throughout the patient encounter. Through the use of Emdeon's comprehensive suite of products and services, which are designed to easily integrate with existing technology infrastructures, customers are able to improve efficiency, reduce costs, increase cash flow and more efficiently manage the complex revenue and payment cycle and clinical information exchange processes. For more information, visit www.emdeon.com.

About ICA

ICA was established to take innovative technology developed by Vanderbilt Medical Center to the broader healthcare market, and now delivers a comprehensive health information exchange (HIE) and care management solution to hospitals, IDNs, communities and states. This patient-centered modular approach offers immediate value and return-on-investment through the delivery of clinical information to the point-of-care improving quality while reducing costs. The solution suite, or volume set, includes CareAlign CareExchange, CareConnect, CareCollaborate, CareMeasure and CareManage.  Each volume provides the technology
'/>"/>

SOURCE Emdeon Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Emdeon Reports Third Quarter 2011 Results
2. Emdeon Announces Support for Electronic Prescribing of Controlled Substances Using the DEA-Allowed Quicker-to-Market Approach
3. Emdeon Acquires Chapin to Enhance Provider-Focused Payment Integrity
4. Emdeon Recommends Secure Interim Solutions to Avert Delays in the Implementation of ePrescribing of Controlled Substances
5. Emdeon Announces Strategic Alliance with Enclarity to Address Industry Problems Created by Inconsistent Provider Data Quality
6. Emdeon to Present at the Piper Jaffray Annual Health Care Conference
7. Cardium Announces Closing of $5.0 Million Equity Financing
8. Uroplasty Announces Enrollment of First Patients in the CONFIDeNT Clinical Study for Treatment of Fecal Incontinence with Urgent® PC
9. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
10. China Sky One Medical Reiterates CEO Sick Leave and Announces Significant Middle Management Resignations
11. WuXi PharmaTech Announces Purchase of Ordinary Shares from General Atlantic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... 2013  AbbVie (NYSE: ABBV ) ... clinical study called SONAR (Study Of Diabetic Nephropathy ... investigational compound atrasentan - when added to standard of ... with stage 2 to 4 chronic kidney disease ... large, multinational, double-blind, placebo-controlled clinical study that is ...
(Date:5/19/2013)... ORLANDO, Fla. , May 19, 2013 /PRNewswire/ ... power and low temperature radiofrequency (RF) energy is ... and eliminates or reduces the need for medication ... long-term assessment presented today at the Digestive Disease ... Orlando, Florida . ...
(Date:5/17/2013)... SHANGHAI , May 17, 2013 Medical ... drug nor a biological product. In light of their ... trail evaluations are much more complicated than drug trails ... only evaluates MD safety instead of evaluating both safety ... the US FDA (which is the same as the ...
Breaking Medicine Technology:AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 2AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 3AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 4AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 5AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy 6Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 2Stretta Procedure for GERD: Successful 10 Year Follow-Up Data Presented at Digestive Disease Week--Sustained Improvement, Long-Term Efficacy 3Statistical Challenges in Medical Device Trail Evaluation 2
... Inc., a market leader in PyroCarbon orthopedic implants, announces ... than 40,000 PyroCarbon extremity joint replacements worldwide. ... of Ascension Orthopedics, pioneered efforts using PyroCarbon in the ... His collaborative efforts with the Mayo Clinic lead to ...
... Reportlinker.com announces that a new market research report ... Probiotics and Prebiotics in Clinical Nutrition ... Overall sales of clinical nutrition products are ... EU as well as rising incidence of illnesses and ...
Cached Medicine Technology:Ascension Orthopedics Reaches Milestone With Distribution of 40,000 PyroCarbon Implants 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 2Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 3Reportlinker Adds Probiotics and Prebiotics in Clinical Nutrition 4
(Date:5/20/2013)... , , MONDAY, May 20 (HealthDay News) -- The older ... the late 1990s is more effective than the current ... Teenagers who received four shots with the older vaccine ... years old were significantly less likely to become infected ... compared to children who received all of their immunizations ...
(Date:5/20/2013)... ARBOR, Mich. As high schoolers prepare for final ... "study drug" -- a prescription stimulant or amphetamine -- ... of Michigan poll shows only one in 100 parents ... has used a study drug., Study drugs refer to ... deficit hyperactivity disorder (ADHD); commonly prescribed medicines in this ...
(Date:5/20/2013)... May 20, 2013 Medicare Part D ... satisfied, citing lower costs, convenient access to pharmacies and ... Research Associates released today by the Pharmaceutical Care Management ... (9.5 million) are currently enrolled in plans with preferred ... and overall value of plans with preferred pharmacy networks,” ...
(Date:5/20/2013)... It’s May which means it’s Bike Month! If you ... those dusty bikes and helmets. , Windsong Production's and BLARE ... the office with Windsong Productions challenging BLARE ... miles for the 4th Annual Million Mile Challenge. They may ... *insert battle prep montage* , This is all part of ...
(Date:5/20/2013)... 20, 2013 6Webs.com is the leading ... reviews . 6Webs.com recently completed their assessments of the ... are completed annually and the top home security system ... their monitoring technology, equipment and warranties to mention a ... the 6Webs.com team completed the home security reviews, numerous ...
Breaking Medicine News(10 mins):Health News:Study: Older Whooping Cough Vaccine More Effective 2Health News:Study: Older Whooping Cough Vaccine More Effective 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2Health News:Survey: 85% of Part D Seniors in Preferred Pharmacy Plans are Satisfied With Costs, Pharmacy Choices 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2
... oral drug bosentan (Tracleer) has led to significant improvements ... PAH) // . ,PAH is usually linked with ... cause the overproduction of endothelin, which increases the chance ... obstruction leads to PAH, a condition that in most ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... to latest research patients who were treated for depression ... vitamin B12 in their blood.// An increasing amount of ... and depression, but the specifics have not been understood. ... of vitamin B12 and the treatment of depression. ...
... researchers find people who get only four hours a night have ... to weight gain. ,An investigation was conducted among 12 ... the study started, after they had slept about four hours a ... hours a night for two nights. Levels of leptin, which sends ...
... the market are losing their effectiveness, since most of ... that the ocean is a new place to look ... microorganisms fill every milliliter of seawater. Each one could ... deadliest diseases. Many marine organisms are already in development ...
... a month’s time from now five-year-old Hussain Abbas and Mohamed ... as normal children.// Part of a contingent of 20 Iraqi ... complicated cardiac problems by the Much Acclaimed heart surgeon Dr ... assessment this evening by a paediatric cardiac physician and are ...
Cached Medicine News:
...
Malis Curette, bayonet, titanium handle, stainless steel shaft, working distance 102 mm, length 203 mm....
Sundt Slim-Line Temporary Vessel Clips used for temporary vascular occlusion during intracranial surgical procedures. Non-magnetic, MP35N, MRI compatible, gold color. Bayonet....
Malis Needle Holders, bayonet, titanium. Working distance 2 1/2" (63 mm). Straight tip with width 0.6 mm....
Medicine Products: